


**Amended Claims:**

1. (Original) A method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I)



(I)

wherein R<sup>1</sup> and R<sup>2</sup> are each independently hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; or a pharmaceutically acceptable salt thereof.

2. (Original) A method according to claim 1 wherein R<sup>2</sup> is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.


3. (Original) A method according to claim 2 wherein R<sup>1</sup> is hydrogen, methyl, ethyl, n-propyl, or isopropyl, or a pharmaceutically acceptable salt thereof.

4. (Original) A method according to claim 1 wherein R<sup>1</sup> is hydrogen and R<sup>2</sup> is methyl, or a pharmaceutically acceptable salt thereof.

5. (Original) A method according to claim 1 wherein said patient is a human diagnosed with prostate cancer.

6. (Original) A method according to claim 1 wherein said patient is a human at risk of developing prostate cancer.

7. (Original) A method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I)



(I)

wherein R<sup>1</sup> and R<sup>2</sup> are each independently hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; or a pharmaceutically acceptable salt thereof.

8. (Original) A method according to claim 7 wherein R<sup>2</sup> is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.


9. (Original) A method according to claim 8 wherein R<sup>1</sup> is hydrogen, methyl, ethyl, n-propyl, or isopropyl, or a pharmaceutically acceptable salt thereof.

10. (Original) A method according to claim 7 wherein R<sup>1</sup> is hydrogen and R<sup>2</sup> is methyl, or a pharmaceutically acceptable salt thereof.

11. (Original) A method according to claim 7 wherein said patient is a human diagnosed with androgen-independent prostatic adenocarcinoma.

12. (Original) A method according to claim 7 wherein said patient is a human at risk of developing androgen-independent prostatic adenocarcinoma.

13. (Withdrawn) A method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I)



(I)

wherein R<sup>1</sup> and R<sup>2</sup> are each independently hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; or a pharmaceutically acceptable salt thereof.

14. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is glioblastoma.

15. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is colon cancer.

16. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is pancreatic cancer.

17. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is ovarian cancer.

18. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is endometrial cancer.

19. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is renal cell cancer.

20. (Withdrawn) A method according to claim 13 wherein R<sup>1</sup> is hydrogen and R<sup>2</sup> is methyl, or a pharmaceutically acceptable salt thereof.

21-36. (Cancelled)